EUR/USD has been riding higher after US inflation fell short of investors' fears. However, overbought conditions and a vaccine scare may cause a pause and prevent the pair from rising above the 1.20 level, FXStreet’s Analyst Yohay Elam reports.
The halting of J&J's vaccine distribution may delay Europe's exit from the covid crisis
“Jerome Powell, Chair of the Federal Reserve, will speak later on and may feel vindicated that his insistence that inflation will be transitory is proving correct – at least for now. The world's most powerful central bank has not only urged patience with inflation but also wants to see a substantial increase in employment before moving. That may take a long time. In the meantime, the dollar could remain under ongoing pressure.”
“The US FDA recommended pausing injecting the firm's immunizations after six cases of rare blood clots among 6.8 million people that were inoculated. The investigation will likely take several days.”
“The euro was hit as J&J promptly decided to pause sending its vaccines to European countries, in an ‘abundance of caution.’ While the US does not depend on the firm's single-shot solution to reach its goals, the old continent may suffer a delay of 3-4 months to reach 70% of its population. Losing another summer season could be devastating.”
“The Relative Strength Index is flirting with 70 – on the verge of overbought conditions and signaling a potential drop.”
“Critical resistance is at 1.1990, which is a double-top from March. It is followed by 1.2025 and 1.2110, levels seen earlier in the year.”
“Support awaits at 1.1950, a resistance line from late March, followed by 1.1925, a cap from last week.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.